Coherus Signs a License Agreement with Innovent Biologics to Commercialize Biosimilar of Avastin (bevacizumab) in the US and Canada
Shots:
- Innovent to receive $45M as upfront- development & regulatory milestone and royalties on sales of the therapy in the licensed territories while Coherus plans to file BLA to the US FDA in H2’20 or H1’21. Additionally- Coherus get an option to commercialize Innovent’s biosimilar to Rituxan (rituximab) in the US and Canada
- If option exercises- financial terms will be the same as a biosimilar to Avastin. The agreement fosters Coherus’ oncology pipeline and leverages its commercial infrastructure in the US
- Innovent’s biosimilar to Avastin has completed its P-III study in China with its accepted NMPA application in 2019 and has received PR status. Addition of Avastin biosimilar complements Coheres’ Udenyca and advance its focus to improve patient access and lower healthcare costs in the US
Click here to read full press release/ article | Ref: Coherus | Image: Coherus
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com